C4 Therapeutics Inc
CCCC2.280USD
+0.010+0.44%
收盘 10/06, 16:00（美东）报价延迟15分钟
161.90M总市值
亏损市盈率 TTM
关于 C4 Therapeutics Inc 公司
C4 Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司专注于推进靶向蛋白质降解科学，以创造新一代小分子药物，改变患者的生活。通过利用其专有的靶向蛋白质降解剂优化器 (TORPEDO) 平台，设计和优化小分子蛋白质降解剂，这些降解剂可针对其所需靶标，利用人体自然过程破坏不需要的蛋白质。其 TORPEDO 平台能够设计两种类型的蛋白质降解剂，两种降解剂方法均反映在其临床管线中。其候选产品 CFT7455 是一种口服生物可利用的 MonoDAC 降解剂，针对 IKZF1 和 IKZF3 蛋白质靶标，目前正在进行多发性骨髓瘤和非霍奇金淋巴瘤的临床开发。其 CFT1946 是一种口服生物可利用的 BiDAC 降解剂，旨在有效且选择性地对抗 BRAF V600X 突变蛋白。该公司还在开发 CFT8919。
C4 Therapeutics Inc简介
公司代码CCCC
公司名称C4 Therapeutics Inc
上市日期Oct 02, 2020
CEOMr. Andrew J. Hirsch
员工数量110
证券类型Ordinary Share
年结日Oct 02
公司地址490 Arsenal Way
城市WATERTOWN
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02472
电话16172310700
网址https://c4therapeutics.com/
公司代码CCCC
上市日期Oct 02, 2020
CEOMr. Andrew J. Hirsch
C4 Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
168.59K
+2.10%
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
107.81K
+90.58%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
105.00K
+36.72%
Mr. Utpal Koppikar
Mr. Utpal Koppikar
Independent Director
Independent Director
5.67K
--
Dr. Stephen Fawell, Ph.D.
Dr. Stephen Fawell, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donna Grogan, M.D.
Dr. Donna Grogan, M.D.
Independent Director
Independent Director
--
--
Ms. Jolie M. Siegel, J.D.
Ms. Jolie M. Siegel, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Courtney Solberg
Ms. Courtney Solberg
Senior Manager - Investor Relations
Senior Manager - Investor Relations
--
--
Dr. Laura Bessen, M.D.
Dr. Laura Bessen, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
168.59K
+2.10%
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
107.81K
+90.58%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
105.00K
+36.72%
Mr. Utpal Koppikar
Mr. Utpal Koppikar
Independent Director
Independent Director
5.67K
--
Dr. Stephen Fawell, Ph.D.
Dr. Stephen Fawell, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donna Grogan, M.D.
Dr. Donna Grogan, M.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Wasatch Global Investors Inc
10.43%
Lynx1 Capital Advisors LLC
9.97%
Soleus Capital Management, L.P.
9.81%
OrbiMed Advisors, LLC
9.60%
Betta investment Hong Kong Ltd
6.85%
其他
53.34%
持股股东
持股股东
占比
Wasatch Global Investors Inc
10.43%
Lynx1 Capital Advisors LLC
9.97%
Soleus Capital Management, L.P.
9.81%
OrbiMed Advisors, LLC
9.60%
Betta investment Hong Kong Ltd
6.85%
其他
53.34%
股东类型
持股股东
占比
Investment Advisor
22.41%
Investment Advisor/Hedge Fund
17.62%
Hedge Fund
17.47%
Private Equity
9.60%
Research Firm
9.51%
Corporation
6.85%
Individual Investor
3.30%
Venture Capital
0.15%
Pension Fund
0.12%
其他
12.98%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
298
54.75M
76.92%
-29.11M
2025Q2
314
71.31M
100.42%
-15.50M
2025Q1
338
73.30M
106.72%
-7.68M
2024Q4
337
73.17M
103.10%
-6.50M
2024Q3
332
72.91M
103.31%
-3.42M
2024Q2
325
69.49M
100.73%
-3.96M
2024Q1
329
66.54M
97.72%
+3.15M
2023Q4
324
51.20M
103.91%
-2.36M
2023Q3
320
38.85M
79.00%
-14.16M
2023Q2
326
38.30M
78.08%
-12.52M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Wasatch Global Investors Inc
7.42M
10.43%
-48.67K
-0.65%
Jun 30, 2025
Lynx1 Capital Advisors LLC
7.10M
9.97%
--
--
Jun 30, 2025
Soleus Capital Management, L.P.
6.98M
9.81%
--
--
Jun 30, 2025
OrbiMed Advisors, LLC
6.83M
9.6%
--
--
Jun 30, 2025
Betta investment Hong Kong Ltd
4.87M
6.85%
-693.38K
-12.45%
Apr 22, 2025
Morgan Stanley & Co. LLC
3.15M
4.43%
+703.45K
+28.70%
Jun 30, 2025
The Vanguard Group, Inc.
3.02M
4.24%
-352.86K
-10.47%
Jun 30, 2025
BofA Global Research (US)
2.01M
2.82%
+17.18K
+0.86%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.70M
2.39%
-3.02M
-64.03%
Jun 30, 2025
Morgan Stanley Investment Management Inc. (US)
1.58M
2.21%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 20 小时前
更新时间: 20 小时前
机构名称
占比
iShares Micro-Cap ETF
0.03%
Fidelity Enhanced Small Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.01%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.03%
Fidelity Enhanced Small Cap ETF
占比0.02%
Invesco RAFI US 1500 Small-Mid ETF
占比0.02%
ProShares Ultra Nasdaq Biotechnology
占比0.02%
Invesco Nasdaq Biotechnology ETF
占比0.02%
iShares Biotechnology ETF
占比0.01%
ProShares Hedge Replication ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
Global X Russell 2000 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
